All members of SPP 2127
Second funding period
- Kevin Achberger
- Marius Ader
- Elvir Becirovic
- Martin Biel
- Volker Busskamp
- Robert Finger
- Florian Giesert
- Jay Gopalakrishnan
- Cord Huchzermeyer
- Mike O. Karl
- Nikolai Klymiuk
- Susanne Kohl
- Stefan Liebau
- Moritz Lindner
- Helen May-Simera
- Kerstin Nagel-Wolfrum
- Thorsten Stafforst
- Knut Stieger
- Bernd Wissinger
- Uwe Wolfrum
- Marius Ueffing
First funding period
- Marius Ader
- Elvir Becirovic
- Martin Biel
- Volker Busskamp
- Cornelia Deeg
- Robert Finger
- Dominik Fischer
- Jay Gopalakrishnan
- Antje Grosche
- Jochen Guck
- Wolf Harmening
- Stefanie Hauck
- Cord Huchzermeyer
- Mike O. Karl
- Nikolai Klymiuk
- Susanne Kohl
- Jan Kremers
- Stefan Liebau
- Birgit Lorenz
- Helen May-Simera
- Stylianos Michalakis
- Kerstin Nagel-Wolfrum
- John Neidhardt
- Diana Pauly
- Mathias Seeliger
- Knut Stieger
- Katarina Stingl
- Marius Ueffing
- Uwe Wolfrum
Members of the SPP 2127
- Achberger
Gene therapy
Second funding period
- Ader
Cell therapy
First funding period
Second funding period
- Becirovic
Gene therapy
First funding period
Second funding period
- Biel
Gene therapy
First funding period
Second funding period
- Busskamp
Gene therapy
First funding period
Second funding period
- Deeg
Factors affecting efficacy of cell and gene therapy
first funding period
- Finger
Listenelement 1
Diagnostics and clinical readout parameter
First funding period
Second funding period
- Fischer
Factors affecting efficacy of cell and gene therapy
First funding period
- Giesert
Gene therapy
Second funding period
- Gopalakrishnan
Cell therapy
First funding period
Second funding period
- Grosche
Factors affecting efficacy of cell and gene therapy
First funding period
- Guck
Cell therapy
First funding period
- Harmening
Listenelement 2
Diagnostics and clinical readout parameter
First funding period
- Hauck
Factors affecting efficacy of cell and gene therapy
First funding period
- Huchzermeyer
Listenelement 3
Diagnostics and clinical readout parameter
First funding period
Second funding period
- Karl
Cell therapy
First funding period
Second funding period
- Klymiuk
Gene therapy
First funding period
Second funding period
- Kohl
Factors affecting efficacy of cell and gene therapy
First funding period
Second funding period
- Kremers
Listenelement 4
Diagnostics and clinical readout parameter
First funding period
- Liebau
Cell therapy
First funding period
Second funding period
- Lindner
Gene therapy
Second funding period
- Lorenz
Diagnostics and clinical readout parameter
First funding period
- May-Simera
Cell therapy
First funding period
Second funding period
- Michalakis
Gene therapy
First funding period
Second funding period
- Nagel-Wolfrum
Cell therapy
First funding period
Second funding period
- Neidhardt
Gene therapy
First funding period
- Pauly
Factors affecting efficacy of cell and gene therapy
First funding period
- Seeliger
Gene therapy
First funding period
- Stafforst
Gene therapy
Second funding period
- Stieger
Gene therapy
First funding period
Second funding period
- Stingl
Diagnostics and clinical readout parameter
First funding period
- Ueffing
Cell therapy
First funding period
Second funding period
- Wissinger
Gene therapy
Second funding period
- Wolfrum
Gene therapy
First funding period
Second funding period